Regeneron, Sanofi to Offer Praluent at Reduced U.S. List Price

Date : 02/11/2019 @ 12:57PM
Source : Dow Jones News
Stock : Sanofi (SAN)
Quote : 75.16  0.26 (0.35%) @ 4:39PM
Sanofi share price Chart

Regeneron, Sanofi to Offer Praluent at Reduced U.S. List Price

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
Historical Stock Chart

6 Months : From Nov 2018 to May 2019

Click Here for more Regeneron Pharmaceuticals, Inc. Charts.

By Michael Dabaie


Regeneron Pharmaceuticals Inc. (REGN) and Sanofi (SNY) said Monday they will offer Praluent at a reduced U.S. list price.

Praluent will be available at a reduced U.S. list price of $5,850 annually, a 60% reduction from the original price, for both the 75 mg and 150 mg doses, beginning in early March.

With the new lower-priced Praluent, most Medicare Part D patients are expected to pay between $25 to $150 per month, depending on their insurance plan, the companies said. Praluent is a treatment for adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease.

The companies in March 2018 committed to lower the U.S. net price for payers in return for helping to reduce access barriers for appropriate patients, the companies said.


Write to Michael Dabaie at


(END) Dow Jones Newswires

February 11, 2019 07:42 ET (12:42 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.
Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:us D:20190524 23:00:40